Cytek Biosciences, Inc. CTKB Accrued Litigation
Accrued Litigation at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LitigationReserveNoncurrent.
The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytek Biosciences, Inc.'s accrued litigation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytek Biosciences, Inc.'s accrued litigation?
- Cytek Biosciences, Inc. (CTKB) reported accrued litigation of $6.64M in Q1 2026.
- How has Cytek Biosciences, Inc.'s accrued litigation changed year-over-year?
- Cytek Biosciences, Inc.'s accrued litigation decreased by 24.7% year-over-year, from $8.82M to $6.64M.
- What is the long-term trend for Cytek Biosciences, Inc.'s accrued litigation?
- Over 5 years (2020 to 2025), Cytek Biosciences, Inc.'s accrued litigation has grown at a -9.1% compound annual growth rate (CAGR), from $10.96M to $6.79M.
- What does accrued litigation mean?
- This metric reflects the estimated financial provisions set aside to cover potential losses or settlements arising from ongoing legal proceedings or disputes. It represents management's current assessment of probable and estimable liabilities related to litigation risks. Tracking this figure provides insight into the company's legal exposure and the potential impact of non-operational contingencies on its financial position.